Eiger BioPharmaceuticals Management
Management criteria checks 2/4
Eiger BioPharmaceuticals' CEO is David Apelian, appointed in Dec 2022, has a tenure of 1.33 years. total yearly compensation is $204.39K, comprised of 15.1% salary and 84.9% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth €443.16. The average tenure of the management team and the board of directors is 1.3 years and 6.6 years respectively.
Key information
David Apelian
Chief executive officer
US$204.4k
Total compensation
| CEO salary percentage | 15.1% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 1.3yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$87m |
| Jun 30 2023 | n/a | n/a | -US$96m |
| Mar 31 2023 | n/a | n/a | -US$97m |
| Dec 31 2022 | US$204k | US$31k | -US$97m |
| Sep 30 2022 | n/a | n/a | -US$93m |
| Jun 30 2022 | n/a | n/a | -US$89m |
| Mar 31 2022 | n/a | n/a | -US$86m |
| Dec 31 2021 | US$149k | n/a | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$31m |
| Jun 30 2021 | n/a | n/a | -US$24m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$102k | n/a | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$63m |
| Jun 30 2020 | n/a | n/a | -US$66m |
| Mar 31 2020 | n/a | n/a | -US$68m |
| Dec 31 2019 | US$2m | US$272k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$70m |
| Jun 30 2019 | n/a | n/a | -US$68m |
| Mar 31 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$3m | US$514k | -US$52m |
| Sep 30 2018 | n/a | n/a | -US$47m |
| Jun 30 2018 | n/a | n/a | -US$39m |
| Mar 31 2018 | n/a | n/a | -US$40m |
| Dec 31 2017 | US$194k | n/a | -US$42m |
Compensation vs Market: David's total compensation ($USD204.39K) is below average for companies of similar size in the German market ($USD394.52K).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
CEO
David Apelian (58 yo)
1.3yrs
Tenure
US$204,386
Compensation
Dr. David Apelian, M.D., Ph D., MBA, served as Chief Executive Officer and Director of Bluesphere Bio, Inc. since July 2019. Dr. Apelian served as Chief Operating Officer and Executive Medical Officer at E...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$204.39k | 0.025% $ 443.2 | |
| Scientific Founder & Independent Director | 8.1yrs | US$134.59k | 0.76% $ 13.6k | |
| CFO and Principal Financial & Accounting Officer | less than a year | no data | no data | |
| Chief Technical Officer | 2yrs | no data | no data | |
| General Counsel | 1.3yrs | no data | no data | |
| Senior Vice President of Clinical & Development Operations | 1.3yrs | no data | no data | |
| Senior Vice President of Metabolic Diseases | 1.3yrs | no data | no data |
1.3yrs
Average Tenure
57.5yo
Average Age
Experienced Management: 72C's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$204.39k | 0.025% $ 443.2 | |
| Scientific Founder & Independent Director | 8.1yrs | US$134.59k | 0.76% $ 13.6k | |
| Independent Chairman | 8.1yrs | US$274.58k | 0.16% $ 2.9k | |
| Independent Director | 5yrs | US$135.09k | 0.036% $ 643.6 | |
| Independent Director | 1.8yrs | US$181.07k | 0% $ 0 | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 6.6yrs | US$137.09k | 0.032% $ 563.7 | |
| Scientific Advisor | no data | no data | no data | |
| Director | 3yrs | US$124.59k | 0.014% $ 241.5 |
6.6yrs
Average Tenure
58yo
Average Age
Experienced Board: 72C's board of directors are considered experienced (6.6 years average tenure).